Public Employees Retirement Association of Colorado reduced its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 17.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,919 shares of the biotechnology company’s stock after selling 2,063 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Enanta Pharmaceuticals were worth $742,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of ENTA. First Manhattan Co. boosted its position in shares of Enanta Pharmaceuticals by 2,820.9% during the 3rd quarter. First Manhattan Co. now owns 969,736 shares of the biotechnology company’s stock valued at $55,090,000 after acquiring an additional 936,536 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new position in Enanta Pharmaceuticals during the 4th quarter valued at about $12,066,000. Hillsdale Investment Management Inc. bought a new position in Enanta Pharmaceuticals during the 4th quarter valued at about $4,035,000. Northern Trust Corp lifted its holdings in Enanta Pharmaceuticals by 5.5% during the 4th quarter. Northern Trust Corp now owns 1,012,164 shares of the biotechnology company’s stock valued at $75,689,000 after purchasing an additional 53,116 shares during the last quarter. Finally, FMR LLC lifted its holdings in Enanta Pharmaceuticals by 19.5% during the 1st quarter. FMR LLC now owns 240,195 shares of the biotechnology company’s stock valued at $22,944,000 after purchasing an additional 39,200 shares during the last quarter. Institutional investors and hedge funds own 98.87% of the company’s stock.
Enanta Pharmaceuticals stock opened at $41.87 on Friday. The stock has a market capitalization of $867.13 million, a PE ratio of -7.59 and a beta of 0.64. Enanta Pharmaceuticals, Inc. has a twelve month low of $38.02 and a twelve month high of $102.00. The company has a 50 day moving average of $65.27 and a 200-day moving average of $69.71.
In other news, VP Nathalie Adda sold 32,785 shares of the stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $72.18, for a total value of $2,366,421.30. Following the transaction, the vice president now directly owns 34,982 shares of the company’s stock, valued at $2,525,000.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce L. A. Carter sold 6,000 shares of the company’s stock in a transaction dated Monday, March 21st. The shares were sold at an average price of $67.83, for a total transaction of $406,980.00. The disclosure for this sale can be found here. In the last three months, insiders sold 113,683 shares of company stock worth $8,084,777. 11.74% of the stock is currently owned by insiders.
ENTA has been the subject of several analyst reports. StockNews.com started coverage on shares of Enanta Pharmaceuticals in a report on Thursday, March 31st. They set a “hold” rating for the company. Oppenheimer dropped their target price on shares of Enanta Pharmaceuticals from $70.00 to $45.00 and set an “outperform” rating for the company in a research note on Friday. Robert W. Baird dropped their target price on shares of Enanta Pharmaceuticals from $130.00 to $90.00 and set an “outperform” rating for the company in a research note on Thursday. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 18th. Finally, SVB Leerink dropped their target price on shares of Enanta Pharmaceuticals from $58.00 to $44.00 and set a “market perform” rating for the company in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Enanta Pharmaceuticals presently has an average rating of “Buy” and an average target price of $74.75.
Enanta Pharmaceuticals Company Profile (Get Rating)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.